{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:48:10Z","timestamp":1790624890677,"version":"4.1.0"},"reference-count":29,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The aim of this study was to evaluate the efficacy and safety of gemcitabine plus nab-paclitaxel (GnP) as second-line chemotherapy following first-line FOLFIRINOX treatment failure in advanced pancreatic cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This was a multicenter, single-arm, open-label, phase 2 trial done at three tertiary centers in South Korea from May 2018 to December 2019. Eligible patients were aged 20\u2009years or older, had histologically confirmed advanced pancreatic ductal adenocarcinoma, and disease progression after receiving first-line FOLFIRINOX. Patients received a second-line GnP regimen as intravenous nab-paclitaxel at a dose of 125\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and gemcitabine at a dose of 1000\u2009mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , on days 1, 8, and 15 every 4\u2009weeks until disease progression or unacceptable toxicity. The primary outcome was survival rate at 6\u2009months and the secondary outcomes were median progression-free survival (PFS), overall survival (OS), disease control rate (DCR), and adverse events. This study is registered with Clinicaltrials.gov. (NCT03401827)\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Forty patients were enrolled in the study. The survival rate at 6\u2009months was 72.5% [95% confidence interval (CI), 59.9\u201387.7], achieving superiority over prespecified assumed 6-month OS rate of 20% for best supportive care only ( p\u2009&lt;\u20090.001). The median PFS and OS were 5.8\u2009months (95% CI, 4.3\u20138.7) and 9.9\u2009months (95% CI, 7.5\u201312.4), respectively. DCR was 87.5% with six partial responses and 29 stable diseases. Grade 3 or higher treatment-related adverse events occurred in 25 (62.5%) patients with the most common being thrombocytopenia, anemia, neutropenia, peripheral neuropathy, and peripheral edema.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>GnP demonstrated favorable efficacy with acceptable toxicity in patients with advanced pancreatic ductal adenocarcinoma after FOLFIRINOX failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359211056179","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T01:08:27Z","timestamp":1636592907000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Gemcitabine plus Nab-paclitaxel as a second-line treatment following FOLFIRINOX failure in advanced pancreatic cancer: a multicenter, single-arm, open-label, phase 2 trial"],"prefix":"10.1177","volume":"13","author":[{"given":"Gunn","family":"Huh","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea"},{"name":"Pancreaticobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Seung","family":"Lee","sequence":"additional","affiliation":[{"name":"Pancreaticobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer, Seoul, Korea"},{"name":"Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Ho","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea"},{"name":"Pancreaticobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hyub","family":"Lee","sequence":"additional","affiliation":[{"name":"Professor, Division of Gastroenterology, Department of Internal Medicine, Seoul National University College of Medicine, Liver Research Institute, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea"},{"name":"Pancreaticobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Hyun","family":"Paik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea"},{"name":"Pancreaticobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Kon","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea"},{"name":"Pancreaticobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Tae","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea"},{"name":"Pancreaticobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungmin","family":"Bang","sequence":"additional","affiliation":[{"name":"Pancreaticobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer, Seoul, Korea"},{"name":"Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eaum Seok","family":"Lee","sequence":"additional","affiliation":[{"name":"Pancreaticobiliary Cancer Study Group of Korean Society of Gastrointestinal Cancer, Seoul, Korea"},{"name":"Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"key":"bibr1-17588359211056179","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21590"},{"key":"bibr2-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31937"},{"key":"bibr3-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30974-0"},{"key":"bibr4-17588359211056179","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma, Version 2. 2021, www.nccn.org\/patients"},{"key":"bibr5-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"bibr6-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"bibr7-17588359211056179","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040484"},{"key":"bibr8-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605374"},{"key":"bibr9-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1875-1"},{"key":"bibr10-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.6995"},{"key":"bibr11-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-441"},{"key":"bibr12-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.5776"},{"key":"bibr13-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1"},{"key":"bibr14-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5383"},{"key":"bibr15-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.328"},{"key":"bibr16-17588359211056179","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8060761"},{"key":"bibr17-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01364"},{"key":"bibr18-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"bibr19-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt166"},{"key":"bibr20-17588359211056179","volume-title":"Statistical models and methods for lifetime data","author":"Lawless JF","year":"2003","edition":"2"},{"key":"bibr21-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/26.4.404"},{"key":"bibr22-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920905408"},{"key":"bibr23-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.462"},{"key":"bibr24-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2049"},{"key":"bibr25-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920923424"},{"key":"bibr26-17588359211056179","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v12.i2.182"},{"key":"bibr27-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01399"},{"key":"bibr28-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1093\/bja\/aex229"},{"key":"bibr29-17588359211056179","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24951"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359211056179","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359211056179","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359211056179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:26:30Z","timestamp":1777587990000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359211056179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":29,"alternative-id":["10.1177\/17588359211056179"],"URL":"https:\/\/doi.org\/10.1177\/17588359211056179","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"17588359211056179"}}